US Tariffs On China Goods Also Target Diagnostics; Industry Preps For USTR Hearing
Executive Summary
As more is learned about China-made medtech products facing a potential 25% US tariff, AdvaMed says some diagnostics would also take a hit and is working with its members to prepare for the upcoming US Trade Representative's public hearing on the impacts.
You may also be interested in...
US Trade Rep Cuts 22 China-Made Devices From Tariffs List, But Retains 27
While the Trump administration appears to have been partially persuaded by industry arguments that a host of China-made medtech items do not belong on a list of items earmarked for a 25% tariff starting July 6, there are still 27 devices – or accessories – that remain.
Industry Gives US Trade Rep 12 Reasons Why Tariffs on Chinese Medtech Imports Are A Bad Idea
The US Trade Representative office's decision in March to include devices, imaging machines and diagnostics on a list of Chinese imports destined for a 25% tariff has riled up the industry. A half-dozen medtech organizations protested the move in comments and testimony this week, supplying USTR with 12 reasons why the tariffs are a very bad idea.
AdvaMed To Plead With USTR To Spare Medtech In China Tariffs
In prepared remarks shared with Medtech Insight, AdvaMed plans to argue that tariffs imposed on medtech products made in China would disrupt an ongoing "action plan" the industry is pursuing to achieve reciprocal market access between the US and China for the industry.